References of "Piel, Géraldine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDevelopment and evaluation of injectable nanosized drug delivery systems for apigenin
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

in International Journal of Pharmaceutics (2017), 532(2), 757-768

The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and ... [more ▼]

The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and compare their characteristics to identify the nanovector(s) that can deliver the largest quantity of AG while being biocompatible. Two liposomes with different surface characteristics (cationic and anionic), a LNC and a PNC were prepared. A novel tocopherol modified poly(ethylene glycol)-b-polyphosphate block-copolymer was used for the first time for the PNC preparation. The NDDSs were compared by their physicochemical characteristics, AG release, storage stability, stability in serum, complement consumption and toxicity against a human macrovascular endothelial cell line (EAhy926). The diameter and surface charge of the NDDSs were comparable with previously reported injectable nanocarriers. The NDDSs showed good encapsulation efficiency and drug loading. Moreover, the NDDSs were stable during storage and in fetal bovine serum for extended periods, showed low complement consumption and were non-toxic to EAhy926 cells up to high concentrations. Therefore, they can be considered as potential injectable nanocarriers of AG. Due to less pronounced burst effect and extended release characteristics, the nanocapsules could be favorable approaches for achieving prolonged pharmacological activity of AG using injectable NDDS. [less ▲]

Detailed reference viewed: 58 (17 ULiège)
Peer Reviewed
See detailIdentification and quantitation of intact virus-like particles of human papillomavirus (HPV-VLP) using capillary electrophoresis
Bettonville, Virginie ULiege; Nicol, Jérôme; Furst, Tania et al

Conference (2017, September 19)

Detailed reference viewed: 40 (2 ULiège)
Full Text
Peer Reviewed
See detailWhole blood microsampling for the quantitation of estetrol without derivatization by liquid chromatography-tandem mass spectrometry
Nys, Gwenaël ULiege; Gallez, Anne ULiege; Kok, Miranda ULiege et al

in Journal of Pharmaceutical & Biomedical Analysis (2017), 140

Detailed reference viewed: 47 (16 ULiège)
Full Text
See detailPromoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment
Lechanteur, Anna ULiege; Furst Tania; Evrard, Brigitte ULiege et al

Conference (2017, April 25)

Detailed reference viewed: 18 (3 ULiège)
Full Text
Peer Reviewed
See detailPromoting vaginal distribution of E7 and MCL-1 siRNA-silencing nanoparticles for cervical cancer treatment
Lechanteur, Anna ULiege; Furst, Tania; Delvenne, Philippe ULiege et al

in Molecular Pharmaceutics (2017)

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailQuantitation and biospecific identification of virus-like particles of human papillomavirus by capillary electrophoresis.
Bettonville, Virginie ULiege; Nicol, Jerome T. J.; Furst, Tania et al

in Talanta (2017), 175

Capillary electrophoresis (CE) for HPV-VLP quantitation is a very interesting alternative technique compared to those currently used in viral analysis, such as SDS-PAGE, Western blot or protein assay that ... [more ▼]

Capillary electrophoresis (CE) for HPV-VLP quantitation is a very interesting alternative technique compared to those currently used in viral analysis, such as SDS-PAGE, Western blot or protein assay that are destructive and semi-quantitative or non specific. In this study, the quantitative performance of the CE method was evaluated. A main issue in virus quantitation is the absence of reference material. Therefore, the concentration of a HPV16-VLP sample produced in the laboratory was determined using ELISA with Gardasil(R), after adjuvant dissolution, as reference material and conformational H16.V5 antibody. HPV16-VLP concentration was found to influence particles electrophoretic mobility until a plateau was reached for concentrations </= 50microgml-1. As zeta potential is directly proportional to the electrophoretic mobility, it was measured at different HPV-VLP concentrations and the results were in complete accordance with the measured electrophoretic mobilities. The concentration dependence of the electrophoretic mobility could be explained by an overlap of the electrical double layers of adjacent particles. The HPV16-VLP peak identity was demonstrated unequivocally by the study of HPV16-VLP/H16.V5 antibody complex formation using affinity CE. Finally, the CE method was successfully validated following the ICH Q2R1 guidelines. To overcome the sample heterogeneity issue, a well-designed sample preparation was used. Considering sample complexity, validation results were satisfactory with maximum repeatability and intermediate precision RSD of 12.2% and a maximum relative bias of 1.4%. [less ▲]

Detailed reference viewed: 24 (1 ULiège)
Full Text
See detailEnhancement of the internalization of lipid nanocapsules in human glioblastoma cells: Effect of surface concentration of NFL peptide
Karim, Reatul ULiege; Lepeltier, Elise; Palazzo, Claudio ULiege et al

Poster (2017)

Le glioblastome multiforme (GBM) est un des cancers les plus fatal, avec une médiane de survie de 14 mois après traitement. Il est donc nécessaire de développer de nouvelles thérapies plus efficaces. La ... [more ▼]

Le glioblastome multiforme (GBM) est un des cancers les plus fatal, avec une médiane de survie de 14 mois après traitement. Il est donc nécessaire de développer de nouvelles thérapies plus efficaces. La fonctionnalisation en surface de nanocapsules lipidiques (LNC) avec le peptide NFL-TBS.40-63 (NFL) a déjà montré une amélioration de leur internalisation dans des cellules de glioblastome murin. Le but de cette étude a été d’évaluer l’impact de la concentration en NFL présente en surface des LNC sur l’internalisation de ces dernières dans des cellules humaines de GBM U87MG. De plus, le mécanisme d’internalisation LNC-NFL a été étudié. Une sonde fluorescente (DiA) a été encapsulé dans : des LNC (F1), des LNC avec 0.86 % et 2.58 % (w/w) de NFL adsorbé à la surface (F2 et F3 respectivement). Des analyses par cytométrie en flux (FACS) ont révélé une internalisation cellulaire de F3 plus importante de 46.4 et 6.8 fois après 30 min, de 21.6 et 6.1 fois après 1 heure, de 31.5 et 1.6 fois après 6 heures et de 7.3 et 1.1 fois après 24 heures, comparés à F1 et F2 respectivement. L’internalisation de F3 dans les cellules U87MG s’est révélée être énergie-dépendant, avec comme mécanisme principal la macropinocytose. Les cinétiques de désorption du peptides (obtenues par dialyse de F3 dans du Tris-Buffer pH 7.4 à 37°C suivi par une HPLC analytique) ont montré que 66 % de NFL restaient à la surface des LNC après 6h de dialyse, montrant une désorption lente. De plus, les trois formulations ont montré une faible activation du complément. Du fait d’une internalisation significativement plus prononcée et rapide, F3 semble être prometteur pour améliorer l’efficacité des thérapies antiGBM. De plus, la lente désorption du NFL de la surface des LNC et la faible consommation du complément font de F3 une thérapie ciblé prometteuse contre le GBM. [less ▲]

Detailed reference viewed: 23 (0 ULiège)
Peer Reviewed
See detailStudy of virus-like particles of human papillomavirus in capillary electrophoresis
Bettonville, Virginie ULiege; Nicol, Jérôme; Furst, Tania et al

Poster (2017)

Detailed reference viewed: 40 (6 ULiège)
Full Text
Peer Reviewed
See detailPEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy
Frère, Antoine ULiege; Baroni, Alexandra; Hendrick, Elodie ULiege et al

in ACS Applied Materials and Interfaces (2017), 25(9(3)), 2181-2195

Guanidine and morpholine functionalized aliphatic polycarbonate polymers are able to efficiently deliver histone deacetylase 5 (HDAC5) siRNA into the cytoplasm of cancer cells in vitro leading to a ... [more ▼]

Guanidine and morpholine functionalized aliphatic polycarbonate polymers are able to efficiently deliver histone deacetylase 5 (HDAC5) siRNA into the cytoplasm of cancer cells in vitro leading to a decrease of cell proliferation were previously developed. To allow these biodegradable and biocompatible polyplex nanoparticles to overcome the extracellular barriers and be effective in vivo after an intravenous injection, polyethylene glycol chains (PEG750 or PEG2000) were grafted on the polymer structure. These nanoparticles, showed an average size of about 150 nm and a slightly positive zeta potential with complete siRNA complexation. Behavior of PEGylated and non-PEGylated polyplexes were investigated in the presence of serum, in terms of siRNA complexation (Fluorescence Correlation Spectroscopy), size (Dynamic Light Scattering and Single-Particle Tracking), interaction with proteins (Isothermal Titration Calorimetry) and cellular uptake. Surprisingly, both PEGylated and non-PEGylated formulations presented relatively good behavior in the presence of fetal bovine serum (FBS). Hemocompatibility tests showed no effect of these polyplexes on hemolysis and coagulation. In vivo biodistribution in mice was performed and showed a better siRNA accumulation at the tumor site for PEGylated polyplexes. However, cellular uptake in protein-rich conditions showed that PEGylated polyplex lost their ability to interact with biological membranes and enter into cells, showing the importance to perform in vitro investigations in physiological conditions closed to in vivo situation. In vitro, the efficiency of PEGylated nanoparticles decreases compared to non-PEGylated particles, leading to the loss of the antiproliferative effect on cancer cells. [less ▲]

Detailed reference viewed: 51 (5 ULiège)
Full Text
See detailNEW INJECTABLE LIPOSOME AND DRUG-IN-CYCLODEXTRIN-IN LIPOSOME SYSTEMS ENCAPSULATING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES IN PREMATURE BABIES
Palazzo, Claudio ULiege; Laloy, Julie; Delvigne, Anne-Sophie et al

Poster (2016, December)

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies ... [more ▼]

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies with motor, vision, hearing or mental deficiencies is still constant along the last twenty years. Moreover, no efficacy treatment is available to the present day. The estetrol (E4) has an important role in the brain development and protection. The aim of this study is to develop new injectable liposome and drug-in-cyclodextrin-in-liposome (DCL) formulations, encapsulating E4 in order to enhance its crossing through the blood-brain barrier (BBB). Methods: Cyclodextrins (CD) were used to increase E4 aqueous solubility. Liposome and DCL (E4-CD complex) formulations were prepared by thin-film hydration technique. The formulations were physicochemical characterized. LDH and MTS tests on endothelial, neuronal and BBB model cells were performed in vitro on the liposome formulation. Hemocompatibility of the formulations was evaluated on red blood cells, platelet aggregation and coagulation. BBB passage tests were performed using human BBB cell line (hCMEC/D3). Results: E4-CD complexes proportionally increased the solubility of the hormone. Liposomes and DCL encapsulating E4 were prepared. All the formulations had average particle size below 150 nm, polydispersity index below 0.10 and ζ potential around + 30 mV. The encapsulation efficacy for liposomes was between 3% and 10% while those of DCL are between 15% and 35%. Moreover, the formulations are capable to release 80 % (liposome) and 90 % (DCL) of encapsulated E4 after 3 h at 37°C. The effect of liposome and DCL formulations on cell viability and integrity was evaluated. The results showed no toxic effects on all the tested cell lines. Hemocompatibility tests showed no hemolysis, platelet aggregation or effects on coagulation, confirming the possibility of the formulations to be intravenously administrated. BBB passage tests highlighted the capability of the formulations to pass the BBB and reach the brain. Conclusions: New non-toxic, hemocompatible liposome and DCL formulations encapsulating E4 were prepared. The formulations are promising drug delivery system to target estrogens to the brain, due to their physiochemical characteristics. [less ▲]

Detailed reference viewed: 66 (7 ULiège)
Full Text
See detailDevelopment and comparison of liposomes and nanocapsules as injectable nanocarriers for poorly aqueous soluble drugs
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

Poster (2016, December)

About 90% of drugs in development phase have poor aqueous solubility. Liposomes and nanocapsules are promising approaches that enable parenteral administration of these drugs with possibilities of site ... [more ▼]

About 90% of drugs in development phase have poor aqueous solubility. Liposomes and nanocapsules are promising approaches that enable parenteral administration of these drugs with possibilities of site specific delivery. The objective of the study was to develop different liposomes and lipid nanocapsules entrapping a hydrophobic model molecule (apigenin (AG)), and to characterize and compare them as potential injectable nanocarriers (NCs) for drugs with low aqueous solubility. [less ▲]

Detailed reference viewed: 86 (10 ULiège)
Peer Reviewed
See detailINNOVATIVE INJECTABLE LIPOSOME AND DRUG-IN-CYCLODEXTRIN-IN LIPOSOME SYSTEMS ENCAPSULATING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES IN PREMATURE BABIES
Palazzo, Claudio ULiege; Laloy, Julie; Delvigne, Anne-Sophie et al

Conference (2016, September 28)

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies ... [more ▼]

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies with motor, vision, hearing or mental deficiencies is still constant along the last twenty years. Moreover, no efficacy treatment is available to the present day. The estetrol (E4) has an important role in the brain development and protection. The aim of this study is to develop new injectable liposome and drug-in-cyclodextrin-in-liposome (DCL) formulations, encapsulating E4 in order to enhance its crossing through the blood-brain barrier (BBB). Methods: Hydroxypropyl-β-cyclodextrins (degrees of substitution 0.87 and 0.63) (HPβCD 0.87 and HPβCD 0.63) were used to increase E4 aqueous solubility. Liposome and DCL (E4-HPβCD 0.63 complex) formulations were prepared by thin-film hydration technique. The formulations were physicochemical characterized and stability in foetal bovine serum (FBS) was evaluated. LDH and MTS tests on endothelial, neuronal and BBB model cells were performed in vitro on the liposome formulation. Hemocompatibility of the formulations was evaluated on red blood cells, platelet aggregation and coagulation. BBB passage tests were performed using human BBB cell line (hCMEC/D3). Results: E4-HPβCD complexes proportionally increased the solubility of the hormone. Due to the lower solubility obtained with HPβCD ds 0.87, only HPβCD ds 0.63 was retained for future tests. Liposomes and DCL encapsulating E4 were prepared. All the formulations had average particle size below 150 nm, polydispersity index below 0.10 and ζ potential around + 30 mV. The encapsulation efficacy for liposomes was between 3% and 10% while those of DCL are between 15% and 35%. Moreover, the formulations are capable to release 80 % (liposome) and 90 % (DCL) of encapsulated E4 after 3 h at 37°C. The formulations, incubated in FBS at 37°C under gentle stirring, keep the same size and do not form protein corona up to 6 h. The effect of liposome and DCL formulations on cell viability and integrity was evaluated. The results showed no toxic effects on all the tested cell lines. Hemocompatibility tests showed no hemolysis, platelet aggregation or effects on coagulation, confirming the possibility of the formulations to be intravenously administrated. Preliminary BBB passage tests highlighted the capability of the formulations to pass the BBB and reach the brain. Conclusions: New non-toxic, hemocompatible liposome and DCL formulations encapsulating E4 were prepared. The formulations are promising drug delivery system to target estrogens to the brain, due to their physiochemical characteristics. Aknowledgment : The authors thank Estetra SPRL for providing Estetrol. [less ▲]

Detailed reference viewed: 81 (10 ULiège)
Peer Reviewed
See detailDEVELOPMENT OF NOVEL CATIONIC AND LIGAND-GRAFTED ANIONIC LIPOSOMES FOR BRAIN-TARGETED DRUG DELIVERY
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

Poster (2016, September 27)

Detailed reference viewed: 33 (3 ULiège)
Peer Reviewed
See detailMUCOADHESIVE SPONGES WITH PEGYLATED LIPOPLEXES: TOWARDS A SUSTAINED VAGINAL DELIVERY OF siRNA
Furst, Tania ULiege; Dakwar, Georges; zagato, Elisa et al

Poster (2016, September 26)

Detailed reference viewed: 20 (3 ULiège)
Full Text
Peer Reviewed
See detailPEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness
Lechanteur, Anna ULiege; Furst, Tania ULiege; Evrard, Brigitte ULiege et al

in European Journal of Pharmaceutical Sciences (2016), 93

Detailed reference viewed: 27 (8 ULiège)
Peer Reviewed
See detailPolymeric Nanoparticles as siRNA Drug Delivery System for Cancer Therapy: The Long Road to Therapeutic Efficiency
Frère, Antoine ULiege; Evrard, Brigitte ULiege; Mottet, Denis ULiege et al

in Holban, Alina Maria; Grumezescu, Alexandru (Eds.) Nanoarchitectonics for Smart Delivery and Drug Targeting (2016)

Polyplexes are nanoparticles composed of small-interfering RNA (siRNA) and natural or synthetic polymers. To meet the challenge of gene therapy and deliver siRNA into the cytoplasm of target cells ... [more ▼]

Polyplexes are nanoparticles composed of small-interfering RNA (siRNA) and natural or synthetic polymers. To meet the challenge of gene therapy and deliver siRNA into the cytoplasm of target cells, several barriers must be overcome. In this chapter, the main steps, from the formulation of polyplexes to the efficient release of the siRNA into the cytoplasm of cancer cells, are described, taking into account the different strategies used to overcome the obstacles linked to the formulation of this type of nanovector. To allow a parenteral administration of the nanocolloids, the polyplex production methods should result in identical, stable, and reproducible nanostructures. Charge interactions occur between the anionic siRNA and the cationic/amphiphilic polymer. Once in the blood circulation, polyplexes must keep their physical stability. The positively charged surface can cause aggregation of the nanoparticles with plasma proteins, as well as complement activation and recognition by the mononuclear phagocytic system, with a consequent reduction of their pharmacological activity. Polyethylene glycol (PEG) can be added on the surface of the nanovectors to confer “the stealth” properties and increase plasma half-life. Then, particles have to preferentially accumulate in the tumor tissue following an active or passive targeting. Endocytosis process enables the polyplex cellular uptake, but some strategies like “the proton sponge effect” have to be used to allow the escape of the nanovectors from the cellular endosomes. Once released into the cytoplasm, polymer and siRNA must dissociate for an effective degradation of the targeted mRNA, leading finally to a decrease of the corresponding protein. [less ▲]

Detailed reference viewed: 161 (9 ULiège)